| Mark Clayton, PHARMD | |
|
767 Admiral Ave, Tulare, CA 93274-1269 | |
| (503) 258-7114 | |
| Not Available |
| Full Name | Mark Clayton |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 767 Admiral Ave, Tulare, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003210766 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 71459 (California) | Primary |
| 183500000X | Pharmacist | PH00066399 (Washington) | Secondary |
| 183500000X | Pharmacist | S018484 (Arizona) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Mark Clayton, PHARMD 767 Admiral Ave, Tulare, CA 93274-1269 Ph: (503) 258-7114 | Mark Clayton, PHARMD 767 Admiral Ave, Tulare, CA 93274-1269 Ph: (503) 258-7114 |
News Archive
Researchers at New York University's Center for Neural Science and the Baylor College of Medicine have identified a protein that when removed from mice results in behaviors that are akin to those with autism and obsessive-compulsive disorders.
eClinicalWorks®, a market leader in ambulatory clinical systems, today announced that California Forensic Medical Group (CFMG), which provides health care to correctional facilities in 25 counties in the state, has selected eClinicalWorks electronic medical records (EMR) system. Using eClinicalWorks will allow the group to streamline operations and improve the quality of care provided through reporting capabilities and the ability to share data across the counties. This will help in the continuity of care for inmates.
A large-scale data review by researchers in China of double balloon enteroscopy (DBE) over the last decade showed the endoscopic procedure to be safe and effective for detection of diseases of the small intestine.
A new study presented today at the 48th Annual American Neurotology Society spring meeting is challenging a long held belief among speech therapists and audiologists that bad behavior in young children with hearing implants is an indicator of device failure and a predictor of poor language development.
Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension--a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).
› Verified 1 days ago
Ann Elise Macias, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2195 E Prosperity Ave, Tulare, CA 93274 Phone: 559-631-1129 Fax: 559-631-1139 | |
Dr. David Diep, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1110 E Prosperity Ave, Tulare, CA 93274 Phone: 559-684-1327 | |
Carlos Augusto Escobar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 109 S West St, Tulare, CA 93274 Phone: 559-687-1953 | |
Irma Feeley, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 110 E Cross Ave, Tulare, CA 93274 Phone: 559-686-1588 | |
Bryan Brassfield, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 49 W Tulare Ave, Tulare, CA 93274 Phone: 559-685-9704 Fax: 559-685-9708 | |
Dr. Matthew Paul Garrett, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 49 W Tulare Ave, Tulare, CA 93274 Phone: 559-685-9704 Fax: 559-685-9708 |